Literature DB >> 7553575

Human antiprotozoal therapy: past, present, and future.

M Khaw1, C B Panosian.   

Abstract

Human protozoal infections are ubiquitous and occur worldwide. In many cases, antiprotozoal agents currently in use predate the modern antibiotic era. Despite the relative lag in development of new antiprotozoal agents, the 1990s have witnessed an increasing level of interest in these infections, inspired by international travel and immigration, a growing awareness of antiprotozoal drug resistance, and the significance of acute and recrudescent protozoal infections in immunosuppressed hosts. This review summarizes for nonclinician readers the past, present, and future therapies for common human protozoal infections, as well as pharmacologic mechanisms of action and resistance and common toxicities associated with these agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553575      PMCID: PMC174634          DOI: 10.1128/CMR.8.3.427

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  170 in total

1.  Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine.

Authors:  J Soto; P Buffet; M Grogl; J Berman
Journal:  Am J Trop Med Hyg       Date:  1994-01       Impact factor: 2.345

2.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

3.  Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial.

Authors:  J McAuley; K M Boyer; D Patel; M Mets; C Swisher; N Roizen; C Wolters; L Stein; M Stein; W Schey
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

Review 4.  Amebiasis and "nonpathogenic" intestinal protozoa.

Authors:  J N Aucott; J I Ravdin
Journal:  Infect Dis Clin North Am       Date:  1993-09       Impact factor: 5.982

5.  Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination.

Authors:  F Nosten; C Luxemburger; F O ter Kuile; C Woodrow; J P Eh; T Chongsuphajaisiddhi; N J White
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

Review 6.  Issues in toxoplasmosis.

Authors:  R McCabe; V Chirurgi
Journal:  Infect Dis Clin North Am       Date:  1993-09       Impact factor: 5.982

7.  A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats.

Authors:  J E Rehg
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

Review 8.  Chagas disease. American trypanosomiasis.

Authors:  L V Kirchhoff
Journal:  Infect Dis Clin North Am       Date:  1993-09       Impact factor: 5.982

Review 9.  Human microsporidial infections.

Authors:  R Weber; R T Bryan; D A Schwartz; R L Owen
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 10.  Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.

Authors:  J Torre-Cisneros; J L Villanueva; J M Kindelan; R Jurado; P Sanchez-Guijo
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

View more
  15 in total

1.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

Review 2.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

3.  Furazolidone is a selective in vitro candidate against Leishmania (L.) chagasi: an ultrastructural study.

Authors:  Juliana Quero Reimão; Noemi Nosomi Taniwaki; André Gustavo Tempone
Journal:  Parasitol Res       Date:  2010-03-30       Impact factor: 2.289

4.  In vitro susceptibility testing of Dientamoeba fragilis.

Authors:  N Nagata; D Marriott; J Harkness; J T Ellis; D Stark
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

5.  Failure of combination therapy with imidocarb dipropionate and toltrazuril to clear Hepatozoon canis infection in dogs.

Authors:  Serdar Pasa; Huseyin Voyvoda; Tulin Karagenc; Abidin Atasoy; Serkal Gazyagci
Journal:  Parasitol Res       Date:  2011-04-07       Impact factor: 2.289

6.  Prevalence of Toxoplasma gondii infection in HIV-infected patients and food animals and direct genotyping of T. gondii isolates, Southern Ghana.

Authors:  Faustina Pappoe; Weisheng Cheng; Lin Wang; Yuanling Li; Dorcas Obiri-Yeboah; Samuel Victor Nuvor; Henock Ambachew; Xiaodong Hu; Qingli Luo; Deyong Chu; Yuanhong Xu; Jilong Shen
Journal:  Parasitol Res       Date:  2017-04-22       Impact factor: 2.289

7.  Temporal analysis of protozoan lysis in a microfluidic device.

Authors:  Michael F Santillo; Michael L Heien; Andrew G Ewing
Journal:  Lab Chip       Date:  2009-07-03       Impact factor: 6.799

8.  Antiplasmodial and antitrypanosomal activity of plants from the Kingdom of Saudi Arabia.

Authors:  Essam Abdel-Sattar; Fathalla M Harraz; Soliman M A Al-Ansari; Sahar El-Mekkawy; Chikara Ichino; Hiroaki Kiyohara; Kazuhiko Otoguro; Satoshi Omura; Haruki Yamada
Journal:  J Nat Med       Date:  2008-12-10       Impact factor: 2.343

Review 9.  Current treatment options for Dientamoeba fragilis infections.

Authors:  Noriyuki Nagata; Deborah Marriott; John Harkness; John T Ellis; Damien Stark
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-09-03       Impact factor: 4.077

10.  Natural Sesquiterpene Lactones Induce Oxidative Stress in Leishmania mexicana.

Authors:  Patricia Barrera; Valeria P Sülsen; Esteban Lozano; Mónica Rivera; María Florencia Beer; Carlos Tonn; Virginia S Martino; Miguel A Sosa
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.